The current approval of Takeda’s Takhzyro pre-filled pen is an addition to the existing 150 mg and 300 mg pre-filled syringes ...

Tremfya was administered subcutaneously for both induction and maintenance, inducing a clinical response in 65% of moderate ...

The FDA has approved label changes for once-monthly Sublocade, helping to reduce possible barriers to treatment initiation ...

Adding engineered human blood vessel-forming cells to islet transplants boosted the survival of the insulin-producing cells ...

Teva Pharmaceuticals and Alvotech have announced the US launch of the Selarsdi (ustekinumab-aekn) injection, a biosimilar to ...

Injectable ART is administered to the gluteal muscle by a healthcare professional. Research might increase accessibility with ...

Transplanting insulin-producing cells along with engineered blood-vessel-forming cells has successfully reversed type 1 ...

The US Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in ...

Q4 2024 and full year 2024 net product revenue of $122.5 million and $417.0 million, respectively –– ARCALYST 2025 net ...

Kiniksa plans to initiate a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis in mid-2025 –– KPL-387 Phase 1 single ascending dose ...

Adding engineered human blood vessel-forming cells to islet transplants boosted the survival of the insulin-producing cells ...

"In addition, the subcutaneous delivery of apomorphine bypasses ... and one case of severe infusion-site cellulitis (which also was resolved). The most common adverse events (incidence of 10% ...